Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Free Report) was the target of a significant drop in short interest in the month of April. As of April 30th, there was short interest totaling 6,999 shares, a drop of 69.2% from the April 15th total of 22,704 shares. Approximately 0.4% of the company’s stock are short sold. Based on an average daily volume of 33,057 shares, the days-to-cover ratio is currently 0.2 days.
Bolt Biotherapeutics Stock Down 5.4%
Shares of NASDAQ BOLT traded down $0.27 during mid-day trading on Friday, reaching $4.73. 8,269 shares of the company’s stock traded hands, compared to its average volume of 25,313. The stock has a market cap of $9.08 million, a P/E ratio of -0.29 and a beta of 1.10. The business has a 50-day simple moving average of $4.60 and a 200 day simple moving average of $5.12. Bolt Biotherapeutics has a 1-year low of $3.91 and a 1-year high of $9.25. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.51 and a quick ratio of 3.59.
Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($4.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.85) by ($1.46). The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $1.50 million. Bolt Biotherapeutics had a negative net margin of 455.15% and a negative return on equity of 100.89%. On average, analysts expect that Bolt Biotherapeutics will post -9.54 EPS for the current fiscal year.
Analysts Set New Price Targets
Get Our Latest Stock Analysis on BOLT
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the business. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Bolt Biotherapeutics during the fourth quarter valued at about $112,000. Renaissance Technologies LLC lifted its position in shares of Bolt Biotherapeutics by 40.3% during the first quarter. Renaissance Technologies LLC now owns 77,225 shares of the company’s stock valued at $312,000 after purchasing an additional 22,200 shares in the last quarter. Shay Capital LLC bought a new position in shares of Bolt Biotherapeutics during the third quarter valued at about $85,000. Susquehanna International Group LLP bought a new position in shares of Bolt Biotherapeutics during the third quarter valued at about $89,000. Finally, Squarepoint Ops LLC lifted its position in shares of Bolt Biotherapeutics by 19.8% during the third quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock valued at $79,000 after purchasing an additional 2,448 shares in the last quarter. 86.70% of the stock is currently owned by institutional investors and hedge funds.
About Bolt Biotherapeutics
Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.
Read More
- Five stocks we like better than Bolt Biotherapeutics
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
